Abstract:Glycosylation is among the most important post-translational modifications for proteins and is of intrinsic complex character compared with DNAs and naked proteins. Indeed, over 50%-70% of proteins in circulation are glycosylated, and the "sweet attachments" have versatile structural and functional implications. Both the configuration and composition of the attached glycans affect the biological activities of consensus proteins significantly. Glycosylation is generated by complex biosynthetic pathways comprising hundreds of glycosyltransferases, glycosidases, transcriptional factors, transporters and the protein backbone. In addition, lack of direct genetic templates and glyco-specific antibodies such as those commonly used in DNA amplification and protein capture makes research on glycans and glycoproteins even more difficult, thus resulting in sparse knowledge on the pathophysiological implications of glycosylation. Fortunately, cutting-edge technologies have afforded new opportunities and approaches for investigating cancer-related glycosylation. Thus, glycans as well as aberrantly glycosylated protein-based cancer biomarkers have been increasingly recognized. This mini-review highlights the most recent developments in glyco-biomarker studies in an effort to discover clinically relevant cancer biomarkers using advanced analytical methodologies such as mass spectrometry, high-performance liquid chromatographic/ultra-performance liquid chromatography, capillary electrophoresis, and lectin-based technologies. Recent clinical-centered glycobiological studies focused on determining the regulatory mechanisms and the relation with diagnostics, prognostics and even therapeutics are also summarized. These studies indicate that glycomics is a treasure waiting to be mined where the growth of cancer-related glycomics and glycoproteomics is the next great challenge after genomics and proteomics.

Pathophysiological roles and applications of glycosphingolipids in the diagnosis and treatment of cancer diseases

Glycosylation in the Tumor Immune Response: the Bitter Side of Sweetness

Biological Roles of Aberrantly Expressed Glycosphingolipids and Related Enzymes in Human Cancer Development and Progression

Glycosphingolipid-mediated apoptosis and tumor therapy:a review

Advances in Analysis of Glycosphingolipids and Related Diseases

Insights into the Role of Sialylation in Cancer Metastasis, Immunity, and Therapeutic Opportunity

Altered glycosylation in cancer: molecular functions and therapeutic potential

Emerging role of MAPK signaling in glycosphingolipid-associated tumorigenesis

The key role of sphingolipid metabolism in cancer: New therapeutic targets, diagnostic and prognostic values, and anti-tumor immunotherapy resistance

Progress of Glycomics in Breast Cancer

Recent Advances in Understanding the Roles of Sialyltransferases in Tumor Angiogenesis and Metastasis.

Aberrant Glycosylation And Cancer Biomarker Discovery: A Promising And Thorny Journey

Bioactive sphingolipids as emerging targets for signal transduction in cancer development

Glycosylation in cancer as a source of biomarkers

Glycosylation Targeting: A Paradigm Shift in Cancer Immunotherapy

Advances in Glycosylation-Mediated Cancer-Targeted Drug Delivery.

The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy

The biological role and immunotherapy of gangliosides and GD3 synthase in cancers

Biochemical Pathways Delivering Distinct Glycosphingolipid Patterns in MDA-MB-231 and MCF-7 Breast Cancer Cells

N-glycan, a biomarker in current cancer diagnosis

Targeting Sphingolipid Metabolism as a Therapeutic Strategy in Cancer Treatment